Crosstalk between adiponectin and IGF-IR in breast cancer

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Mauro, Loredana ^a   Naimo, Daniela ^a   Ricchio, Emilia ^a   Panno, Maria Luisa ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Adiponectin; Breast cancer; Estrogen receptor; Insulin like growth factor i receptor (IGF IR); Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; AROMATASE; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TUBERIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CELL ADHESION; ESTROGEN ACTIVITY; GENETIC PREDISPOSITION; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; ONCOGENE C MYC; ONCOGENE SRC; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84934275177     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00157     Document Type: Article

References (97)

1. James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. (2015). Obesity in breast cancer-What is the risk factor? Eur J Cancer pii: S0959-8049(15)00101-X. doi: 10.1016/j.ejca.2015.01.057.
2. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, et al. (2004). Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 279:19908-15.
3. Surmacz E. (2013). Leptin and adiponectin: emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia 18:321-32. doi: 10.1007/s10911-013-9302-8.
4. Kadowaki T and Yamauchi T. (2005). Adiponectin and adiponectin receptors. Endocr Rev 26:439-51.
5. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. (2001). Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-5.
6. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102-7.
7. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9:5699-704.
8. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. (2005). Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28:1263-9.
9. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, et al. (2008). Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20:971-7.
10. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. (2008). Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98:370-9. doi: 10.1038/sj.bjc.6604166.
11. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. (2007). Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92:1041-8.
12. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345:271-9.
13. Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. (2009). Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 16:1197-210. doi: 10.1677/ERC-09-0043
14. Treeck O, Lattrich C, Juhasz-Boess I, Buchholz S, Pfeiler G, Ortmann O. (2008). Adiponectin differentially affects gene expression in human mammary epithelial and breast cancer cells. Br J Cancer 99:1246-50. doi: 10.1038/sj.bjc.6604692.
15. Pfeiler GH, Buechler C, Neumeier M, Schäffler A, Schmitz G, Ortmann O, et al. (2008). Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 19:787-93.
16. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, et al. (2009). Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 15:3265-76. doi: 10.1158/1078-0432.CCR-08-2649.
17. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62:10-29. doi: 10.3322/caac.20138.
18. DeSantis C, Siegel R, Bandi P, Jemal A. (2011). Breast cancer statistics, 2011. CA Cancer J Clin 61:409-18. doi: 10.3322/caac.20134
19. Singletary SE. (2003). Rating the risk factors for breast cancer. Ann Surg 237:474-82.
20. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL, et al. (2005). Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14:1686-91.
21. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. (2003). Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21:1961-6.
22. Sundaram S, Johnson AR, Makowski L. (2013). Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog 12:19. doi: 10.4103/1477-3163.119606.
23. Osborn O, Olefsky JM. (2012). The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18:363-74. doi: 10.1038/nm.2627.
24. Andò S, Catalano S. (2011). The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 8:263-75. doi: 10.1038/nrendo.2011.184.
25. Vona-Davis L, Rose DP. (2007). Adipokines as endocrine, paracrine and autocrine factors in breast cancer risk and progression. Endocr. Related Cancer 14:189-206.
26. Wolin KY, Carson K, Colditz GA. (2010). Obesity and cancer. Oncologist 15:556-65. doi: 10.1634/theoncologist.2009-0285.
27. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. (2013). Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 19: 6074-83. doi:10.1158/1078-0432.CCR-12-2603.
28. Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, et al. (2001). The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol Metab 86:4321-5.
29. Saito K, Tobe T, Minoshima S, Aakawa S, Sumiya J, Yoda M, et al. (1999). Organization of the gene for gelatin-binding protein (GBP28). Gene 229:67-73.
30. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, et al. (2000). Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861-8.
31. Shapiro L, Scherer PE. (1998). The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8:335-8.
32. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-32.
33. Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. (2002). Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin: potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 277:19521-9.
34. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. (2003). Structurefunction studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278:9073-85.
35. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. (2002). Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359-62.
36. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. (2003). Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-63.
37. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. (2001). Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005-10.
38. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, et al. (2005). Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146:790-6.
39. Chandran M, Phillips SA, Ciaraldi T, Henry RR. (2003). Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442-50.
40. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, et al. (2003). Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocytespecific secretory protein adiponectin. Diabetes 52:268-76.
41. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, et al. (2005). Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-80.
42. Galic S, Oakhill JS, Steinberg GR. (2010). Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316:129-39. doi: 10.1016/j.mce.2009.08.018.
43. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. (2006). Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 110:267-78.
44. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. (2002). Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-6.
45. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. (2002). Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-7.
46. Tilg H, Moschen AR. (2006). Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-83.
47. Dalamaga M, Diakopoulos KN, Mantzoros CS. (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33:547-94. doi: 10.1210/er.2011-1015.
48. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. (2010). Adiponectin action from head to toe. Endocrine 37:11-32. doi: 10.1007/s12020-009-9278-8.
49. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-9.
50. Wang H, Zhang H, Jia Y, Zhang Z, Craig R, Wang X, et al. (2004). Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes 53:2132-6.
51. Chen X, Wang Y. (2011). Adiponectin and breast cancer. Med Oncol 28:1288-95. doi: 10.1007/s12032-010-9617-x.
52. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. (2003). Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-8.
53. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. (2004). T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 101:10308-13.
54. Asada K, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, et al. (2007). Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats. Int J Mol Med 20:725-9.
55. Chan DW, Lee JM, Chan PC, Ng IO. (2008). Genetic and epigenetic inactivation of Tcadherin in human hepatocellular carcinoma cells. Int J Cancer 123:1043-52. doi: 10.1002/ijc.23634.
56. Lee MH, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM. (2008). The adiponectin receptors AdipoR1 and AdipoR2 activate ERK1/2 through a Src/Ras-dependent pathway and stimulate cell growth. Biochemistry 47:11682-92. doi: 10.1021/bi801451f.
57. Buechler C, Wanninger J, Neumeier M. (2010). Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways. FEBS Lett 584:4280-6. doi: 10.1016/j.febslet.2010.09.035.
58. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. (2006). APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8:516-23.
59. Obeid S, Hebbard L. (2012). Role of adiponectin and its receptors in cancer. Cancer Biol Med 9:213-20. doi: 10.7497/j.issn.2095-3941.2012.04.001.
60. Deepa SS, Dong LQ. (2009). APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296:E22-36. doi: 10.1152/ajpendo.90731.2008.
61. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. (2003). Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52:1355-63.
62. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. (2007). Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-9.
63. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. (2001). The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-6.
64. Merdad A, Karim S, Schulten HJ, Jayapal M, Dallol A, Buhmeida A, et al. (2015). Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of Adiponectin and Fatty Acid Binding Protein4: Is lipid metabolism associated with breast cancer? BMC Genomics 16:S11. doi: 10.1186/1471-2164-16-S1-S11.
65. Korkaya H, Liu S, Wicha MS. (2011). Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121:3804-09. doi: 10.1172/JCI57099.
66. Wang Y. (2011). Adiponectin and breast cancer. Med Oncol 28:1288-95. doi: 10.1007/s12032-010-9617-x.
67. Inoki K, Zhu T, Guan KL. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
68. Luo Z, Saha AK, Xiang X, Ruderman NB. (2005). AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69-76.
69. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, et al. (2005). Adenosine monophosphateactivated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 97:837-44.
70. Mauro L, Pellegrino M, De Amicis F, Ricchio E, Giordano F, Rizza P, et al. (2014). Evidences that estrogen receptor a interferes with adiponectin effects on breast cancer cell growth. Cell Cycle 13 553-64. doi: 10.4161/cc.27455.
71. Mauro L, Pellegrino M, Giordano F, Ricchio E, Rizza P, De Amicis F, et al. (2015). Estrogen receptor-a drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB J 29:2150-60. doi: 10.1096/fj.14-262808.
72. Khan S, Shukla S, Sinha S, Meeran SM. (2013). Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 24:503-13. doi: 10.1016/j.cytogfr.2013.10.001.
73. Surmacz E, Otvos L. (2015). Molecular targeting of obesity pathways in cancer. Horm Mol Biol Clin Investig pii: /j/hmbci.ahead-of-print/hmbci-2015-0007/hmbci-2015-0007.xml. doi: 10.1515/hmbci-2015-0007.
74. Surmacz E. (2000). Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5:95-105.
75. Baserga R. (2000). The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19:5574-81.
76. Mauro L, Bartucci M, Morelli C, Andò S, Surmacz E. (2001). IGF-I receptor-induced cellcell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 276:39892-7.
77. Le Roith D. (2000). Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor. Growth Horm IGF Res10:S12-3.
78. Mauro L, Salerno M, Morelli C, Boterberg T, Bracke ME, Surmacz E. (2003). Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J Cell Physiol 194:108-16.
79. Mauro L, Surmacz E. (2004). IGF-I receptor, cell-cell adhesion, tumour development and progression. J Mol Histol 35:247-53.
80. Seccareccia E, Brodt P. (2012). The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res 22:193-9. doi: 10.1016/j.ghir.2012.09.003.
81. Kaleko M, Rutter WJ, Miller AD. (1990). Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10:464-73.
82. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, et al. (1992). Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ 3:199-205.
83. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. (2008). Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-46. doi: 10.1158/0008-5472.CAN-08-2755.
84. Pollak MN, Schernhammer ES, Hankinson SE. (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-18.
85. Stewart AJ, Johnson MD, May FE, Westley BR. (1990). Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172-8.
86. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, et al. (1999). Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787-96.
87. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, et al. (2001). Estradiol increases IRS-1 gene expression and insulin signaling. Biochem. Biophys. Res. Commun 288:685-9.
88. Salerno M, Sisci D, Mauro L, Guvakova MA, Andò S, Surmacz E.(1999). Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 81:299-304, 1999.
89. Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, et al. (2008) Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets 8:597-610.
90. Gao J, Chang YS, Jallal B, Viner J. (2012). Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 72(1):3-12. doi: 10.1158/0008-5472.CAN-11-0550.
91. Janssen JA, Varewijck AJ. (2014). IGF-IR Targeted Therapy: Past, Present and Future. Front Endocrinol 5:224. doi: 10.3389/fendo.2014.00224.
92. LeRoith D, Roberts CT. (2003). The insulin-like growth factor system and cancer. Cancer Lett 195:127-37.
93. Chabrolle C, Tosca L, Dupont J. (2007). Regulation of adiponectin and its receptors in rat ovary by human chorionic gonadotrophin treatment and potential involvement of adiponectin in granulosa cell steroidogenesis. Reproduction 133:719-31.
94. Ryu J, Galan AK, Xin X, Dong F, Abdul-Ghani MA, Zhou L, et al. (2014). APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep 7:1227-38. doi: 10.1016/j.celrep.2014.04.006.
95. Jia Z, Liu Y, Cui S. (2014). Adiponectin induces breast cancer cell migration and growth factor expression. Cell Biochem Biophys 70:1239-45. doi: 10.1007/s12013-014-0047-9.
96. Saxena NK, Sharma D. (2010). Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 4:358-62.
97. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D. (2009). LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28:2621-33. doi: 10.1038/onc.2009.129